TEMOZOLOMIDE IN MALIGNANT ASTROCYTIC GLIOMAS
- Authors: Borisov K.E.1, Sakayeva D.D.1
-
Affiliations:
- Republican Clinical Dispensary, Ministry of Health of the Republic of Bashkortostan
- Issue: Vol 17, No 1 (2012)
- Pages: 41-48
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/39963
- DOI: https://doi.org/10.17816/onco39963
- ID: 39963
Cite item
Full Text
Abstract
The review of literature provides information on the use of temozolomide in the treatment of malignant astrocytic gliomas. The drug is the standard chemotherapy for recurrent malignant gliomas, by being superior to other agents in relapse-free survival rates, without substantially affecting overall survival. Temozolomide is also a standard component of chemoradiotherapy for new-onset glioblastoma multiforme. A combination of temozolomide and other drugs does not outperform monotherapy with the former in most cases. However, there is its synergism with platinum preparations and the inhibitors of topoisomerase and integrin receptor, which makes it urgent to develop new treatments against for gliomas. Alternative temozolomide regimens may be useful in overcoming the resistance to the drug and in minimizing its toxicity.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
K. E. Borisov
Republican Clinical Dispensary, Ministry of Health of the Republic of Bashkortostan
Email: konstantin9671@rambler.ru
канд. мед. наук Ufa
D. D. Sakayeva
Republican Clinical Dispensary, Ministry of Health of the Republic of BashkortostanUfa
References
- Roos W. P., Batista L. F., Naumann S. C. et al. // Oncogene. 2007. Vol. 26. P. 186-197.
- Nakasu S., Fukami T., Jito J., Matsuda M. // Surg. Neurol. 2007. Vol. 68, N 6. P. 603-608.
- Qian C. C., Brent T. P. // Cancer Res. 1997. Vol. 57. P. 3672-3677.
- Balana C., Carrato C., Ramirez J. et al. // Proc. Am. Soc. Clin. Oncol. 2008. Abstr. 2037.
- Wong E. T., Hess K. R., Gleason M. J. et al. // J. Clin. Oncol. 1999. Vol. 17, N 8. P. 2572-2578.
- Yung W. K., Albright R. E., Olson J. et al. // Br. J. Cancer. 2000. Vol. 83. P. 588-593.
- Qian Z. Z., Wang H. Q., Liu X. M. et al. // Zhonghua Yi Xue Za Zhi. 2009. Vol. 89, N 29. P. 2059-2062.
- Kapelle A. C., Postma T. J., Taphoorn M. J. B. et al. // Neurology. 2001. Vol. 56. P. 118-120.
- Brada M., Stenning S., Gabe R. et al. // J. Clin. Oncol. 2010. - Vol. 28, N 30. P. 4601-4608.
- Ziobro M., Rolski J., Grela-Wojewoda A. et al. // Neurol. Neurochir. Pol. 2008. Vol. 42, N 3. P. 210-215.
- Bower M., Newlands E. S., Bleehen N. M. et al. // Cancer Chemother. Pharmacol. 1997. Vol. 40, N 6. P. 484-488.
- Harris M. T., Rosenthal M. A., Ashley D. L., Cher L. // J. Clin. Neurosci. 2001. Vol. 8, N 4. P. 325-327.
- Brada M., Hoang-Xuan K., Rampling R. et al. // Ann. Oncol. 2001. Vol. 12, N 2. P. 259-266.
- Chang S. M., Theodosopoulos P., Lamborn K. et al. // Cancer. 2004. Vol. 100, N 3. P. 605-611.
- Yung W. K., Prados M. D., Yaya-Tur R. et al. // J. Clin. Oncol. - 1999. Vol. 17, N 9. P. 2762-2771.
- Nishikawa R., Shibui S., Maruno M. et al. // Gan To Kagaku Ryoho. 2006. Vol. 33, N 9. P. 1279-1285.
- Teixeira M. M., Garcia I., Portela I. et al. // Int. J. Clin. Pharmacol. Res. 2002. Vol. 22, N 1. P. 19-22.
- Brandes A. A., Ermani M., Basso U. et al. // Oncology. 2002. Vol. 63, N 1. P. 38-41.
- Trent S., Kong A., Short S. C. et al. // J. Neurooncol. 2002. - Vol. 57, N 3. P. 247-251.
- Fine H. A., Dear K. B. G., Loeffler J. S. et al. // Cancer. - 1993. Vol. 71, N 8. P. 2585-2597.
- Stewart L. A. // Lancet. 2002. Vol. 359. P. 1011-1018.
- Brandes A. A., Vastola F., Basso U. et al. // Cancer. 2003. - Vol. 97, N 3. P. 657-662.
- Brandes A. A., Nicolardi L., Tosoni A. et al. // Neuro-Oncology. 2006. Vol. 8, N 3. P. 253-260.
- Wedge S. R., Porteous J. K., Glaser M. G. et al. // Anticancer Drugs. 1997. Vol. 8. P. 92-97.
- Stupp R., Dietrich P. Y., Ostermann Kraljevic S. et al. // J. Clin. Oncol. 2002. Vol. 20, N 5. P. 1375-1382.
- Stupp R., Mason W. P., van den Bent M. J. et al. // N. Engl. J. Med. 2005. Vol. 352, N 10. P. 987-996.
- Hegi M. E., Diserens A. C., Gorlia T. et al. // N. Engl. J. Med. 2005. Vol. 352, N 10. P. 997-1003.
- Athanassiou H., Synodinou M., Maragoudakis E. et al. // J. Clin. Oncol. 2005. Vol. 23, N 10. P. 2372-2377.
- Combs S. E., Gutwein S., Schulz-Ertner D. et al. // Strahlenther. Onkol. 2005. Bd 181, N 6. S. 372-377.
- Sridhar T., Gore A., Boiangiu I. et al. // Clin. Oncol. (R. Coll. Radiol.). 2009. Vol. 21, N 1. P. 19-22.
- Combs S. E., Wagner J., Bischof M. et al. // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 70, N 4. P. 987-992.
- Minniti G., De Sanctis V., Muni R. et al. // J. Neurooncol. 2008. Vol. 88, N 1. P. 97-103.
- De Sanctis V., Mazzarella G., Osti M. F. et al. // Anticancer Drugs. 2006. Vol. 17, N 8. P. 969-975.
- Vinjamuri M., Adumala R. R., Altaha R. et al. // J. Neurooncol. 2009. Vol. 91, N 2. P. 221-225.
- Штефан А. Ю. Химиолучевое лечение злокачественных глиом головного мозгас применением тенипозида: Автореф. дис.. канд. мед. наук. Уфа, 2007.
- Balzarotti M, Ciusani E., Calatozzolo C. et al. // Oncol. Res. - 2004. Vol. 14, N 7-8. P. 325-330.
- Balana C., Ramirez J. L., Taron M. et al. // Clin. Cancer Res. 2003. Vol. 9, N 4. P. 1461-1468.
- Balana C., Lopez-Pousa A., Berrocal A. et al. // J. Neurooncol. 2004. Vol. 70, N 3. P. 359-369.
- Brandes A. A., Basso U., Reni M. et al. // J. Clin. Oncol. 2004. Vol. 22, N 9. P. 1598-1604.
- Silvani A., Eoli M., Salmaggi A. et al. // J. Neurooncol. 2004. Vol. 66, N 1-2. P. 203-208.
- Chua A. L., Rosenthal M. A., Wong S. S. et al. // Neuro-Oncology. 2004. Vol. 6, N 1. P. 38-43.
- Glas M., Koch H., Hirschmann B. et al. // Oncology. 2007. - Vol. 72, N 5-6. P. 302-307.
- Gruber M. L., Buster W. P. // Am. J. Clin. Oncol. 2004. Vol. 27, N 1. P. 33-38.
- Fountzilas G., Karkavelas G., Kalogera-Fountzila A. et al. // Anticancer Res. 2006. Vol. 26, N 6. P. 4675-4686.
- Newland E. S., Foster T., Zaknoen S. // Br. J. Cancer. 2003. - Vol. 89. P. 248-251.
- Herrlinger U., Rieger J., Koch D. et al. // J. Clin. Oncol. 2006. Vol. 24, N 4. P. 412-417.
- Baumann F., Bjeljac M., Kollias S. S. et al. // J. Neurooncol. 2004. Vol. 67, N 1-2. P. 191-200.
- Riva M., Imbesi F., Beghi E. et al. // Anticancer Res. 2007. - Vol. 27, N 2. P. 1067-1071.
- Kesari S., Schiff D., Henson J. W. et al. // Neuro-Oncology. 2008. Vol. 10, N 3. P. 300-308.
- Groves M. D., Puduvalli V. K., Chang S. M. et al. // J. Neurooncol. 2007. Vol. 81, N 3. P. 271-277.
- Groves M.J.D., Puduvalli V. K., Conrad C. A. et al. // J. Neurooncol. 2006. Vol. 80, N 1. P. 83-90.
- Grossman S. A., Ye X., Piantadosi S. et al. // Clin. Cancer Res. - 2010. Vol. 16, N 8. P. 2443-2449.
- Newlands E. S., Stevens M. F. G., Wedge S. R. et al. // Cancer Treat. Rev. 1997. Vol. 23. P. 35-61.
- Tolcher A. W., Gerson S. L., Denis L. et al. // Br. J. Cancer. 2003. Vol. 23. P. 1004-1011.
- Wong S., Rosenthal M. A., Dowling A. et al. // J. Clin. Neurosci. 2006. Vol. 13, N 1. P. 18-22.
- Wick A., Felsberg J., Steinbach J. P. et al. // J. Clin. Oncol. 2007. Vol. 25, N 22. P. 3357-3361.
- DAmico A., Gabbani M., Dall’oglio S. et al. // J. Clin. Oncol. 2006. Vol. 24 (suppl.). P. 75s. Abstr. 1572.
- Brandes A. A., Tosoni A., Cavallo G. et al. // Br. J. Cancer. 2006. Vol. 95. P. 1155-1160.
- Neyns B., Chaskis C., Joosens E. et al. // Cancer Invest. 2008. Vol. 26. P. 269-277.
- Strik H. M., Buhk J. H., Bock C. et al. // Proc. Am. Soc. Clin. Oncol. 2008. Abstr. 13016.
- Jauch T., Hau P., Bogdahn U. et al. // J. Clin. Oncol. 2007. - Vol. 25 (suppl.). P. 83s. Abstr. 2034.
- Perry J. R., Belanger K., Mason W. P. et al. // J. Clin. Oncol. - 2010. Vol. 28, N 12. P. 2051-2057.
- Kong D. S., Lee J. I., Kim J. H. et al. // Neuro-Oncology. - 2010. Vol. 12, N 3. P. 289-296.
- DAgostino G., Balducci M., Anile C. et al. // J. Clin. Oncol. 2007. Vol. 25 (suppl.). P. 83s. Abstr. 2035.